Thrombolysis for acute ischemic stroke

Journal of Vascular Surgery

Volumn 54, Issue 3, 2011, Pages 901-907

  Hajjar, Karim ^a   Kerr, Daniel M ^a   Lees, Kennedy R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DESMOTEPLASE; FIBRINOLYTIC AGENT; NASARUPLASE BETA; PLACEBO; PROUROKINASE; UROKINASE;

ARTICLE; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; FUNCTIONAL STATUS; HUMAN; MORTALITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

BRAIN ISCHEMIA; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 80052545504     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2011.04.062     Document Type: Article

References (30)

1. C. Mathers, D.M. Fat, J.T. Boerma World Health Organization The global burden of disease: 2004 update 2008 World Health Organization Geneva, Switzerland
2. D. Lloyd-Jones, R.J. Adams, T.M. Brown, M. Carnethon, S. Dai, G. De Simone American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215
3. Tissue plasminogen activator for acute ischemic stroke The National Institute of Neurological Disorders and Stroke Rt-PA Stroke Study Group N Engl J Med 333 1995 1581 1587
4. W. Hacke, M. Kaste, C. Fieschi, D. Toni, E. Lesaffre, and R. von Kummer Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke The European Cooperative Acute Stroke Study (ECASS) JAMA 274 1995 1017 1025
5. W. Hacke, M. Kaste, C. Fieschi, R. von Kummer, A. Davalos, and D. Meier Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Second European-Australasian Acute Stroke Study Investigators Lancet 352 1998 1245 1251 (Pubitemid 28470336)
6. W. Hacke, M. Kaste, E. Bluhmki, M. Brozman, A. Dávalos, and D. Guidetti Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke N Engl J Med 359 2008 1317 1329
7. W.M. Clark, S. Wissman, G.W. Albers, J.H. Jhamandas, K.P. Madden, and S. Hamilton Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke JAMA 282 1999 2019 2026
8. W.M. Clark, G.W. Albers, K.P. Madden, and S. Hamilton The rtPA (alteplase) 0-to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study Thromblytic Therapy in Acute Ischemic Stroke Study Investigators Stroke 31 2000 811 816
9. S.M. Davis, G.A. Donnan, M.W. Parsons, C. Levi, K.S. Butcher, A. Peeters EPITHET Investigators Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial Lancet Neurol 7 2008 299 309
10. W. Hacke, G. Albers, Y. Al-Rawi, J. Bogousslavsky, A. Davalos, and M. Eliasziw The desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase Stroke 36 2005 66 73 (Pubitemid 40054177)
11. W. Hacke, A.J. Furlan, Y. Al-Rawi, A. Davalos, J.B. Fiebach, and F. Gruber Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (Dias-2): a prospective, randomised, double-blind, placebo-controlled study Lancet Neurol 8 2009 141 150
12. A.J. Furlan, D. Eyding, G.W. Albers, Y. Al-Rawi, K.R. Lees, and H.A. Rowley Dose Escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset Stroke 37 2006 1227 1231 (Pubitemid 43731867)
13. G.J. del Zoppo, R.T. Higashida, A.J. Furlan, M.S. Pessin, H.A. Rowley, and G.M. Proact A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism Stroke 29 1998 4 11 (Pubitemid 28046933)
14. A. Furlan, R. Higashida, L. Wechsler, M. Gent, H. Rowley, and C. Kase Intra-arterial pro-urokinase for acute ischemic stroke The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral thromboembolism JAMA 282 1999 2003 2011
15. A. Ogawa, E. Mori, K. Minematsu, W. Taki, A. Takahashi, S. Nemoto MELT Japan Study Group Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan Stroke 38 2007 2633 2639 (Pubitemid 47493996)
16. W. Hacke, G. Donnan, C. Fieschi, M. Kaste, R. von Kummer, J.P. Broderick ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS Rt-PA stroke trials Lancet 363 2004 768 774
17. K.R. Lees, E. Bluhmki, R. von Kummer, T.G. Brott, D. Toni, and J.C. Grotta Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials Lancet 375 2010 1695 1703
18. N.K. Mishra, G.W. Albers, S.M. Davis, G.A. Donnan, A.J. Furlan, W. Hacke, and K.R. Lees Mismatch-based delayed thrombolysis: a meta-analysis Stroke 41 2010 e25 e33
19. J.D. Fields, P. Khatri, G.M. Nesbit, K.C. Liu, S.L. Barnwell, and H.L. Lutsep Meta-analysis of randomized intra-arterial thrombolytic trials for the treatment of acute stroke due to middle cerebral artery occlusion J Neurointerv Surg 2011 in press
20. N. Ahmed, N. Wahlgren, M. Grond, M. Hennerici, K.R. Lees, R. Mikulik SITS Investigators Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR Lancet Neurol 9 2010 866 874
21. N. Wahlgren, N. Ahmed, A. Dávalos, G.A. Ford, M. Grond, W. Hacke SITS-MOST investigators Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study Lancet 369 2007 275 282 (Pubitemid 46138121)
22. N. Wahlgren, N. Ahmed, N. Eriksson, F. Aichner, E. Bluhmki, A. Dávalos Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) Stroke 39 2008 3316 3322
23. N.K. Mishra, N. Ahmed, G. Andersen, J.A. Egido, P.J. Lindsberg, P.A. Ringleb VISTA collaborators; SITS collaborators Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive BMJ 341 2010 c6046
24. N.K. Mishra, S.M. Davis, M. Kaste, K.R. Lees VISTA Collaboration Comparison of outcomes following thrombolytic therapy among patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA) Diabetes Care 33 2010 2531 2537
25. N.K. Mishra, P. Lyden, J.C. Grotta, K.R. Lees VISTA Collaborators Thrombolysis is associated with consistent functional improvement across baseline stroke severity: a comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA) Stroke 41 2010 2612 2617
26. G.W. Albers, W.M. Clark, K.P. Madden, and S.A. Hamilton ATLANTIS trial: results for patients treated within 3 hours of stroke onset Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke Stroke 33 2002 493 495
27. M.D. Hill, A.M. Buchan Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators Thrombolysis for acute ischemic stroke: Results of the Canadian Alteplase for Stroke Effectiveness Study CMAJ 172 2005 1307 1312 (Pubitemid 40745072)
28. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke The NINDS t-PA Stroke Study Group Stroke 28 1997 2109 2118
29. B. Cucchiara, S.E. Kasner, D. Tanne, S.R. Levine, A. Demchuk, S.R. Messe SAINT Investigators Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute ischemic NXY Treatment (SAINT) I and SAINT II Trials Stroke 40 2009 3067 3072
30. J.L. Saver, J. Gornbein, J. Grotta, D. Liebeskind, H. Lutsep, and L. Schwamm Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial Stroke 40 2009 2433 2437